Amneal Pharmaceuticals, Inc. (AMRX) Income Statement

The sequential acceleration in revenue growth, from 3.9% to 9.9% YoY, aligns with the company's reported expansion into biosimilars, which likely contributed to higher volume and pricing. The 2025Q4 revenue of $814.3M, up 11.5% YoY, indicates a strong finish to the year, but the dip in 2026Q1 suggests some quarter-to-quarter volatility. Investors should monitor whether this growth is sustainable as biosimilar competition intensifies.

The 550 basis point improvement in gross margin over two quarters suggests that the product mix is shifting away from low-margin commodity generics toward complex generics and biosimilars. This is a critical driver for the company's profitability, as it offsets the high fixed-cost structure. However, the gross margin remains below peers like Teva (51.8%), indicating room for further improvement if the specialty pipeline performs.

The operating margin expansion of over 400 basis points year-over-year, despite only a 9.9% revenue increase, suggests that SG&A and R&D expenses are growing slower than revenue. This implies that the company is achieving economies of scale, particularly in its specialty and biosimilar segments. However, the 2025Q3 operating loss of -$117K highlights the volatility in the business, likely due to one-time charges or R&D spikes.

The reduction in R&D intensity, from $63.4M in 2025Q3 to $41.1M in 2026Q2, suggests that the company is prioritizing near-term profitability over pipeline investment, which could be a concern for long-term growth. SG&A has remained relatively flat, indicating that the company is not scaling overhead with revenue, which is a positive sign for operating leverage. However, the high fixed-cost structure and debt service requirements remain a drag on net income.